Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectGenetically modified T cells for the treatment of malignant diseaseCustomized targeted therapy in Hodgkin lymphoma: hype or hope?Immunotherapy: opportunities, risks and future perspectivesInduction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcomaGeneration of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cellsSustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.Identification of miR-145 targets through an integrated omics analysis.Genetically modified T-cell therapy for osteosarcomaMyeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine modelProteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunityAdoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.Epigenetic alterations in osteosarcoma: promising targets.Cancer-testis antigens and immunotherapy in the light of cancer complexity.Oncogenic cancer/testis antigens: prime candidates for immunotherapy.Emerging immunotherapy in pediatric lymphoma.Improving cancer immunotherapy with DNA methyltransferase inhibitors.MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.T-cell therapies for HIV: Preclinical successes and current clinical strategies.Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.
P2860
Q26745842-0AB576A8-A41A-48AD-A759-8D6271AEC787Q26775720-63D1C97C-3362-4D11-96CD-36A297ED8C44Q26826830-FA36E05B-9B17-4C13-A85E-137D271F6365Q26860657-886E690F-828C-457B-840D-6B8D60C64A2EQ27002554-B4A99C49-B65F-4C80-AB08-25D436C743C4Q33941012-034CC591-903D-4B94-852B-F809D6112901Q34786566-E07106E2-A7A6-4C89-89B9-EA000C83203DQ34803707-01FED505-BAD1-490D-9083-B386DA8CE57AQ34935239-E0EF455F-3233-47CF-BA02-F1BC6C4536C5Q35067995-622B3E51-9157-4359-9788-9E0A9270BE33Q35068768-9FA4C3CB-8144-4B43-B47B-7A7F54237DE8Q35155627-10514E1B-D879-4590-BD36-462DEB6D9F49Q36198232-7154D0C2-9D94-4319-8B68-BA90AFBDD7FAQ36503123-719E86F8-57A2-4F52-B201-C2B2809A246FQ36596837-882A8650-BCDC-4720-807F-6C34C62DC0C1Q37142367-2429A91F-A74C-487A-B3D8-E2319B91C3E6Q37242561-F4D4F99E-4A15-42CB-B46A-07E138F26323Q37585487-97EDD4D3-8304-4623-A687-5DFACF8E3F0DQ38068839-4F4527E1-D5D8-454B-A821-C18AB6C07E4BQ38185555-F52A864D-ECC4-460F-8BFF-3F03DC195516Q38435410-46976EE9-F1F9-4E8A-9E13-1B4A9C1A4397Q38544350-FC30E978-D8F9-4C5E-9928-088CFF3A5880Q38652326-B9EDEFD8-3F66-423F-8D93-B234240A8559Q38662760-4A2C4F4A-AC89-426A-8B6F-AFE05A62608BQ38753922-6BDB857F-EC2B-42B6-84FD-24823C356CBFQ38856090-0BE923BB-F4D1-4703-95F5-534D2FD68A18Q39064900-7B042D7A-0C1D-4A08-8B5F-98550049825DQ41247038-5519C9ED-8A8C-4AA7-A54B-0581A9487841Q41660817-E7C800D7-7DD1-4E5F-A4CD-17CB7BDB9FB0Q55279130-2D8FAF5F-CC2D-4418-A64E-CEFF5FB7A571
P2860
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Improving T-cell therapy for r ...... targeting upregulated MAGE-A4
@ast
Improving T-cell therapy for r ...... targeting upregulated MAGE-A4
@en
type
label
Improving T-cell therapy for r ...... targeting upregulated MAGE-A4
@ast
Improving T-cell therapy for r ...... targeting upregulated MAGE-A4
@en
prefLabel
Improving T-cell therapy for r ...... targeting upregulated MAGE-A4
@ast
Improving T-cell therapy for r ...... targeting upregulated MAGE-A4
@en
P2093
P2860
P1476
Improving T-cell therapy for r ...... targeting upregulated MAGE-A4
@en
P2093
Amanda Copeland
Anas Younes
Andrea Sheehan
Ann M Leen
Benjamin Tzou
Catherine M Bollard
Cliona M Rooney
Conrad R Cruz
Helen E Heslop
Jessica A Shafer
P2860
P304
P356
10.1158/1078-0432.CCR-11-1873
P407
P577
2011-09-09T00:00:00Z